Faro JP, Bishop K, Riddle G, Ramirez MM, Katz AR, Turrentine MA, Faro S. Accuracy of an accelerated, culture-based assay for detection of group B streptococcus.
Infect Dis Obstet Gynecol 2013;
2013:367935. [PMID:
23509420 PMCID:
PMC3590750 DOI:
10.1155/2013/367935]
[Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2012] [Revised: 01/07/2013] [Accepted: 01/13/2013] [Indexed: 11/22/2022] Open
Abstract
OBJECTIVE
To determine the validity of a novel Group B Streptococcus (GBS) diagnostic assay for the detection of GBS in antepartum patients.
STUDY DESIGN
Women were screened for GBS colonization at 35 to 37 weeks of gestation. Three vaginal-rectal swabs were collected per patient; two were processed by traditional culture (commercial laboratory versus in-house culture), and the third was processed by an immunoblot-based test, in which a sample is placed over an antibody-coated nitrocellulose membrane, and after a six-hour culture, bound GBS is detected with a secondary antibody.
RESULTS
356 patients were evaluated. Commercial processing revealed a GBS prevalence rate of 85/356 (23.6%). In-house culture provided a prevalence rate of 105/356 (29.5%). When the accelerated GBS test result was compared to the in-house GBS culture, it demonstrated a sensitivity of 97.1% and a specificity of 88.4%. Interobserver reliability for the novel GBS test was 88.2%.
CONCLUSIONS
The accelerated GBS test provides a high level of validity for the detection of GBS colonization in antepartum patients within 6.5 hours and demonstrates a substantial agreement between observers.
Collapse